South San Francisco, United States
Lyell Immunopharma, a United States-based biotechnology firm, is pioneering the development of next-generation CAR T-cell therapies aimed at cancer treatment. Founded in 2018 by cell therapy pioneers, the company leverages cutting-edge technology to enhance T cells with characteristics of resistance to exhaustion and durable stemness. This innovation aims to provide consistent and long-lasting clinical responses in its late-stage clinical pipeline.
As of July 2025, Lyell secured a $50.00 million private placement investment to further its research and expansion. The firm's integrated structure supports a seamless transition from discovering new technologies to manufacturing and evaluating therapies in clinical settings. Their commitment to the principles of Science, Respect, Collaboration, and Courage is evident in their process and company culture, reflecting a profound urgency in executing their mission to combat cancer effectively.
Kite Pharma
